Reuters logo
10 个月前
BRIEF-Clovis Oncology presents efficacy, safety data from NDA population for Rucaparib in treatment of advanced mutant BRCA Ovarian cancer
2016年10月7日 / 下午12点57分 / 10 个月前

BRIEF-Clovis Oncology presents efficacy, safety data from NDA population for Rucaparib in treatment of advanced mutant BRCA Ovarian cancer

Oct 7 (Reuters) - Clovis Oncology Inc :

* Prescription drug user fee act (PDUFA) date is February 23, 2017

* Clovis Oncology presents efficacy and safety data from new drug application (NDA) population for Rucaparib in the treatment of advanced mutant BRCA ovarian cancer at 2016 ESMO congress

* European Marketing Authorization Application (MAA) submission planned for Q4 2016 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below